|
Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells. The said drug is equivalent to reference listed drug, Ibrance tablets.
The product will be manufactured at the group's formulation manufacturing facility in SEZ, Ahmedabad (India).
Accroding to IQVIA MAT April 2023, Palbociclib Tablets, had annual sales of $3.3 billion in the United States.
The group now has 373 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.
The scrip closed 1.96% higher to end at Rs 582.05 on Wednesday, 28 June 2023.
|